

# PKC $\alpha$ and HMGB1 antagonistically control hydrogen peroxide-induced poly-ADP-ribose formation

Anneli Andersson<sup>1,2,†</sup>, Andrej Bluwstein<sup>1,3,†</sup>, Nitin Kumar<sup>4</sup>, Federico Teloni<sup>1,2</sup>, Jens Traenkle<sup>5</sup>, Michael Baudis<sup>4</sup>, Matthias Altmeyer<sup>1</sup> and Michael O. Hottiger<sup>1,\*</sup>

<sup>1</sup>Department of Molecular Mechanisms of Disease, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland, <sup>2</sup>Molecular Life Sciences PhD Program, Life Science Zurich Graduate School, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland, <sup>3</sup>Cancer Biology PhD Program, Life Science Zurich Graduate School, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland, <sup>4</sup>Institute of Molecular Life Science (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland and <sup>5</sup>Bayer Technology Services GmbH, D-51368 Leverkusen, Germany

Received October 29, 2015; Revised May 4, 2016; Accepted May 6, 2016

## ABSTRACT

Harmful oxidation of proteins, lipids and nucleic acids is observed when reactive oxygen species (ROS) are produced excessively and/or the antioxidant capacity is reduced, causing ‘oxidative stress’. Nuclear poly-ADP-ribose (PAR) formation is thought to be induced in response to oxidative DNA damage and to promote cell death under sustained oxidative stress conditions. However, what exactly triggers PAR induction in response to oxidative stress is incompletely understood. Using reverse phase protein array (RPPA) and in-depth analysis of key stress signaling components, we observed that PAR formation induced by H<sub>2</sub>O<sub>2</sub> was mediated by the PLC/IP3R/Ca<sup>2+</sup>/PKC $\alpha$  signaling axis. Mechanistically, H<sub>2</sub>O<sub>2</sub>-induced PAR formation correlated with Ca<sup>2+</sup>-dependent DNA damage, which, however, was PKC $\alpha$ -independent. In contrast, PAR formation was completely lost upon knockdown of PKC $\alpha$ , suggesting that DNA damage alone was not sufficient for inducing PAR formation, but required a PKC $\alpha$ -dependent process. Intriguingly, the loss of PAR formation observed upon PKC $\alpha$  depletion was overcome when the chromatin structure-modifying protein HMGB1 was co-depleted with PKC $\alpha$ , suggesting that activation and nuclear translocation of PKC $\alpha$  releases the inhibitory effect of HMGB1 on PAR formation. Together, these results identify PKC $\alpha$  and HMGB1 as important co-regulators involved in H<sub>2</sub>O<sub>2</sub>-induced PAR formation, a finding that may have important relevance for oxidative stress-associated pathophysiological conditions.

## INTRODUCTION

Reactive oxygen species (ROS) are a group of chemical species that contain at least one oxygen atom, but display stronger reactivity than molecular oxygen. ROS can typically arise from exogenous sources such as UVA or  $\gamma$ -irradiation, drugs, heavy metals (1–3), or from endogenous sources e.g. oxidative metabolism, apoptosis, bystander cells or enzymatic activity (4–7). When ROS are produced excessively or antioxidant capacity is reduced, indiscriminate oxidation of proteins, lipids and nucleic acid elicits harmful effects, known as ‘oxidative stress’. ROS as well as the more stable and less reactive by-product of ROS production, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), are more than toxic products of respiratory burst, they are also effectors for a plethora of signaling pathways inducing innate and adaptive immune cell recruitment, cell proliferation, tissue healing, cell survival and apoptosis (8–11).

ADP-ribosylation is a post-translational protein modification that consists of mono- and poly-ADP-ribose (PAR) molecules covalently linked to specific residues of target proteins (12). The linear or branched PAR polymer can consist in vitro of up to 200–400 ADP-ribose moieties linked by *O*-glycosidic 1′-2′ ribose-ribose bonds. These modifications are synthesized by a subfamily of ADP-ribosyltransferases (ARTs), which use NAD<sup>+</sup> as a substrate and belong to the ART diphtheria toxin-like (ARTD, originally PARP) family. In humans, the ARTD family is comprised of 18 members, which contain a characteristic catalytic ART domain conferring enzymatic activity (13). Most of the family members are mono-ARTs, while ARTD9 and ARTD13 are so far found to be inactive and ARTD1, ARTD2, ARTD5 and ARTD6 also catalyze poly-ADP-ribosylation.

The best-characterized ARTD family member is ARTD1 (originally PARP1), a 116 kDa nuclear enzyme consisting of an N-terminal DNA-binding domain (DBD), a central

\*To whom correspondence should be addressed. Tel: +41 44 635 54 74; Fax: +41 44 635 54 68; Email: michael.hottiger@dmmd.uzh.ch

† These authors contributed equally to the paper as first authors.

automodification domain (AMD) and a C-terminal catalytic domain (CAT) (14). ARTD1 automodifies itself at the AMD (15) and modifies other target proteins such as histones, transcription factors and DNA repair proteins, which points at an important function of ADP-ribosylation in epigenetics, transcriptional regulation and repair (16). Indeed, ADP-ribosylation is implicated in the regulation of a plethora of cellular processes, biological phenomena and medical conditions (14,16,17). ARTD1 has recently been termed a ‘cellular rheostat’, because it integrates different types and levels of stress signals (14). In response to mild or moderate stresses, it regulates transcription and DNA repair, while upon severe and sustained stress conditions, hyper-activation of ARTD1 leads to apoptosis or necrosis (18,19). Interestingly, a series of studies has shown that ARTD1 is not only automodified in the presence of DNA damages, but also by specific DNA structures such as cruciform hairpins (20). Moreover, ARTD1 activity can also be stimulated by polyamines (spermine) or core histones (H1 and H3), indicating that DNA-independent mechanisms can activate ARTD1 *in vitro* as well (21). The phosphorylation of H2A<sup>Ser137</sup> can also stimulate ARTD1 activity, and the acetylation of H2A<sup>Lys5</sup> further enhances ARTD1 activity (22). The fact that single histones as well as modified histones stimulate PAR formation, suggests an important role of chromatin for the activation of ARTD1. However, by which mechanism chromatin activates PAR formation *in vivo* has not been elucidated previously. HMGB1 is a chromatin-associated protein that plays a role in the organization, sliding and incorporation of nucleosomes (23–25), as well as the compaction of chromatin (26). There is evidence that the nucleosome occupancy in cells lacking HMGB1 changes globally over the genome and that the DNA is more accessible to MNase digestion (27). Post-translational modifications of HMGB1 can lead to changes in its localization, as well as in its binding to DNA and various DNA structures (28–30), and thus to bend DNA and modify chromatin structure (24,31).

Cellular signaling pathways regulate ARTD1 activity also independently of DNA damage. For example, positive regulation of ARTD1 activity has been described for the extracellular signal-regulated kinase (ERK) (32–34) as well as for c-Jun N-terminal kinase (JNK) (35), while both positive and negative effects of protein kinase C (PKC) signaling in the regulation of ARTD1 have been reported (36–39). The activation of ARTD1 independent of DNA damage adds an additional layer to the traditional view that considers ARTD1 as part of the DNA damage response induced upon genotoxic or oxidative stress. Upon oxidative stress, ROS are believed to produce oxidative DNA damage and cause DNA strand breaks in the nucleus, which then strongly stimulates the enzymatic activity of ARTD1 and induces the formation of PAR (12). However, until now it has not been determined whether ARTD1 is activated by oxidative DNA damage *in vivo* or whether other pathways stimulate ADP-ribosylation in response to oxidative stress.

In this work, we deliberately interrupted the cellular signaling pathways induced early upon stimulation of cells with H<sub>2</sub>O<sub>2</sub> to elucidate the molecular mechanisms involved in PAR formation. Using a systematic reverse phase protein array (RPPA) approach and in-depth molecular anal-

ysis of the key signaling components, we identified activation of the PLC/IP3R/Ca<sup>2+</sup>/PKC $\alpha$  signaling axis as a key regulator of PAR formation. Ca<sup>2+</sup>-dependent signaling induced DNA damage very rapidly (within a few minutes) that, however, was not sufficient to induce PAR formation, since knockdown of PKC $\alpha$  completely abolished PAR formation, but not DNA damage. Moreover, our results show that PKC $\alpha$  activation leads to the nuclear reduction of HMGB1, which otherwise negatively regulates PAR formation. Together these findings identify a major so far underappreciated mechanism, involving PKC $\alpha$  and HMGB1, by which H<sub>2</sub>O<sub>2</sub> stimulates PAR formation.

## MATERIALS AND METHODS

### Cell culture, siRNA transfection, lysis and proliferation assay

MRC-5 and IMR-90 human lung fibroblasts (40,41) were obtained from the American Type Culture Collection (ATCC) and cultured in MEM (Invitrogen) supplemented with 5% penicillin/streptomycin (P/S) and 10% fetal calf serum (FCS). NIH/3T3 were obtained from ATCC and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented with 5% P/S and 10% FCS. Mouse embryonic fibroblasts (MEFs) were cultivated in supplemented DMEM. Cells were pre-incubated with inhibitors (stocks dissolved in dimethyl sulfoxide, used at 1:1000) for 1 h prior to H<sub>2</sub>O<sub>2</sub> treatment in FCS-free media, which was also used as a vehicle for H<sub>2</sub>O<sub>2</sub>. All inhibitors were obtained from Enzo Life Sciences, except for Olaparib (AstraZeneca), PD98059 (Santa Cruz), IKK VII and KN-93 (Merck Millipore), and used at a final concentration as indicated in the figures or figure legends. To specifically reduce ARTD1, PKC $\alpha$ / $\delta$ , PKC pan, HMGB1, IP3R or PLC $\gamma$  expression, 2  $\times$  10<sup>5</sup> NIH/3T3, 1  $\times$  10<sup>5</sup> MRC-5 cells or 2.5  $\times$  10<sup>4</sup> MEFs were transfected using mouse siARTD1 (QIAGEN, SI02731428), siPKC $\alpha$  (QIAGEN, SI01388583), siPKC $\delta$  (QIAGEN, SI01388744), siHMGB1 (Microsynth, sense: 3’-CCGCTGAAAAGAGCAAGAAAA-5’), siIP3R1 (QIAGEN, SI01079092), siIP3R3 (QIAGEN, SI01079106), siPLC $\gamma$ 1 (QIAGEN, SI01380869) or siPLC $\gamma$ 2 (QIAGEN, SI02747381), or human siARTD1 (Microsynth, 3’-GGUGAUCGGUAGCAACAAA-5’), siPKC pan (Santa Cruz Biotechnology, sc-29449), siHMGB1 (QIAGEN, SI03650374), or siMock (QIAGEN, scrambled sequence) lacking significant homology to any known human or mouse gene sequence, with Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s instructions. Cells were treated with H<sub>2</sub>O<sub>2</sub> 3–4 days after transfection. Whole cell lysates were prepared with standard RIPA lysis buffer (50 mM Tris/pH 8, 400 mM NaCl, 0.5% NP-40, 1% deoxycholic acid, 0.1% sodium dodecyl sulphate supplemented with proteinase inhibitor cocktail (Roche), 10 mM  $\beta$ -glycerolphosphate, 1 mM NaF and 1 mM DTT) and total protein concentration determined using the standard Lowry method (42). Nuclear and cytosolic fractions were prepared as described by Dignam *et al.* (43). Cell viability was determined by the MTT assay (Sigma).

### Reverse phase protein arrays (RPPA)

RPPA was performed as described (44,45). In brief, whole cell lysates were spotted onto hydrophobically coated Zeptosens Chips (Bayer Technology Services GmbH). Serially diluted lysates (100, 75, 50 and 25%) were arrayed in duplicates onto hydrophobic Zeptosens Chips using the Nanoplotter NP2.0 (GeSiM), followed by blocking in an ultrasonic nebulizer (ZeptoFOG, Bayer Technology Services GmbH). Antibody incubation with a target specific primary antibody and a signal generating fluorophore-labeled secondary antibody (Invitrogen), microarray data acquisition (ZeptoREADER, Bayer Technology Services GmbH) and data analysis (ZeptoVIEW version 3.1.0.2, Bayer Technology Services GmbH) were performed exactly as described (46). The fluorescence signals obtained from the eight lysate spots (100, 75, 50, 25% lysate amount in duplicates) were fitted using a signal/spot-quality weighted linear least squares fit (47,48) and the relative fluorescence intensity (RFI value) determined at the median protein concentration or modification. To correct for small variations in protein content, relative intensities were normalized to the signals of  $\beta$ -catenin, which itself did not show any significant variation (ANOVA,  $P < 0.05$ ) in response to  $H_2O_2$  over 10–60 min.

### Significance and clustering analysis

To identify significant proteome changes in response to  $H_2O_2$ , relative fluorescence intensities were imported to MultiExperiment Viewer (MeV) version 4.6 (49). Relative fluorescence intensities were  $\log_2$  transformed and normalized, before performing statistical analysis using one-way ANOVA as described in (50). The mean transformed fluorescence intensities for group 1 (biological duplicates of untreated.10 min), group 2 (biological duplicates of 0.5 mM.10 min), group 3 (biological duplicates of 0.5 mM.60 min) were compared using F-statistics with  $P < 0.05$ . For fold-change analysis,  $\log_2$  transformed means of the biological replicates were normalized to the untreated sample (set as 1) and proteome changes were filtered (cut off set at  $1 \times SD$  equal to  $\log_2 > 0.77 / \leq 0.77$  for 0.5 mM). Significant proteome changes in response to  $H_2O_2$  were selected for clustering analysis (Supplementary Figure S2A), if significant by one-way ANOVA ( $P < 0.05$ ). To correct for potential false negatives or positives, significance analysis was performed using fold change cut off with thresholds described above or performing a quality control analysis by visualization (V.C.) for clustering analysis as shown Supplementary Figure S2C. Similar profiles of the fold changes over time were identified by clustering analysis using the k-means clustering algorithm and default parameters of MeV (49). K-means based clustering analysis in Figure 1F comprises significant proteome changes, identified by ANOVA ( $n = 2$ ,  $P < 0.05$ ), fold change cut off (1 SD) and/or visual control (V.C.) and thus might slightly differ from the results obtained by k-means clustering using only ANOVA ( $n = 2$ ,  $P < 0.05$ ) in Supplementary Figure S2A.

### Pathway and network analysis

Gene pathway membership data were obtained from the protein interaction databases PID (51) and KEGG (52). A total of 200 and 211 pathways were obtained from PID and KEGG, respectively. A list of 93 pathways from PID and 63 from KEGG was obtained by mapping the analyzed proteins (unique IDs) to the pathways they play a role in and only selecting for pathways containing at least five of the analyzed proteins.

Fisher's exact test was performed to identify pathways significantly affected by proteins (or modifications) altered in response to  $H_2O_2$  (significant by ANOVA and fold-change) using the R statistical framework (53).  $P$ -values were corrected for multiple testing using the Benjamini-Hochberg correction (54). We have used a false discovery rate (FDR)-corrected  $P$ -value cut off of 0.1 to identify pathways significantly affected by proteome changes.

Significant proteome changes, identified by statistical (ANOVA) and fold-change analysis ( $\log_2$  cut off) were subjected to protein-protein interaction analysis using STRING (v 9.0) (55). Only interactions with a STRING score of at least 0.7 were further analyzed using Cytoscape (<http://www.cytoscape.org/>) (56).


### Immunoblotting

For western blot analysis, proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and bands were visualized by either using horseradish peroxidase-conjugated antibodies (1:5'000, GE Healthcare) and ECL detection (GE Healthcare) or by using IR-Dye-conjugated antibodies (1:15'000, LI-COR) and detection by the Odyssey infrared imaging system (LI-COR). For quantification, bands were analyzed by ImageJ 1.46 (35) and the Odyssey imaging software (LI-COR).

Antibodies used for Western blotting were anti-ARTD1 (Santa Cruz), anti-PKC $\alpha$  (CST), anti-PKC- $\delta$  (CST), anti-Tubulin (1:10'000, Sigma), anti-HMGB1 (1:5'000 abcam), anti-H3 (1:5'000 abcam). If not stated otherwise, antibody dilution was 1:1'000.

### Immunofluorescence (IF) microscopy

For PAR IF analysis  $1.5 \times 10^5$  NIH/3T3 or  $2.5 \times 10^4$  MEF, MRC-5, or IMR-90 cells were grown on coverslips overnight, prior to 1 h pre-incubation with inhibitors and subsequent  $H_2O_2$  treatment. After the indicated time of treatment, cells were washed once with phosphate buffered saline (PBS), fixed with ice-cold methanol and acetic acid (3:1) for 10 min at 4°C, washed three times with PBS, blocked in 5% milk/0.05% Tween-20 in PBS for 30 min and stained immunohistochemically with primary mouse anti-poly(ADP-ribose) IgG (10H, made in-house), rabbit anti-poly(ADP-ribose) (Enzo), mouse anti-myc (Santa-Cruz) or rabbit anti-HMGB1 (abcam). Next, cells were washed three times with PBS before hybridization with a secondary antibody (Cy3 conjugated anti-mouse IgG, Jackson ImmunoResearch or Alexa Fluor 488 conjugated anti-rabbit IgG, Invitrogen). All antibodies were used at a dilution of 1:250. After incubation, cells were mounted on



**Figure 1.** Sublethal H<sub>2</sub>O<sub>2</sub> treatment activates cytoplasmic kinases. (A) PAR immunofluorescence (IF) intensity of MRC-5 cells treated with 0.01–2 mM H<sub>2</sub>O<sub>2</sub> for 3–60 min or left untreated as arbitrary units (a.u.). (B) WT and ARTD1 knockout MEFs were treated with 0.5 mM H<sub>2</sub>O<sub>2</sub> for 10 min. Nuclear

glass slides using DAPI-containing VECTASHIELD (Vector Labs) and images acquired using an inverted fluorescence microscope at 40 $\times$ , oil immersion (Leica). Fluorescence intensities were quantified using ImageJ (v. 1.46r) or Imaris (v. 7.6.0, Bitplane) and equal set-up between the images and experiments.

### Quantitative image-based cell cycle staging

For quantitative image-based cell cycle staging of MEFs, automated wide-field microscopy was performed as described (57,58) with the following modifications: Images were acquired on a Leica DMI 6000 inverted microscope equipped with a motorized stage, a Tri-band bandpass filter (DAPI/FITC/TX; BP387/11/BP 494/20/BP 575/20) and a 12-bit monochrome EMCCD camera (Leica DFC 350 FX, 1392  $\times$  1040 pixels, 6.4  $\mu$ m pixel size). Automated image acquisition under non-saturating conditions was performed using the Leica Matrix Screening Software. All images were imported to the Olympus ScanR Image Analysis Software Version 2.5.1, a dynamic background correction was applied and nuclei segmentation was performed using an integrated intensity-based detection module. Pulsed 5-ethynyl-2'-desoxyuridine (EdU) incorporation, PAR levels and DAPI intensities were measured. G1 cells were identified based on their low EdU and low DAPI content, S phase cells based on their high EdU content, and G2 cells based on their low EdU and high DAPI content.

### *In vitro* kinase and ARTD1 automodification assay

For PKC $\delta$  kinase assay, 0.2  $\mu$ l recombinant PKC catalytic subunit of the PKC $\delta$  isoform from rat brain (Sigma, P1609) and 1  $\mu$ g ARTD1 full-length (fl.) or ARTD1 fragments (fr.) in PKC $\delta$  kinase buffer (120 mM Tris/pH 7.5, 40 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 2 mM DTT) and 20 nM ATP (Sigma) were spiked with 0.74 MBq gamma-labeled ATP (20 nM) and incubated for 30 min. For PKC $\alpha$  kinase assay, 100 ng recombinant PKC $\alpha$  (Enzo, BML-SE494-0005) was incubated in PKC $\alpha$  kinase buffer (25 mM MOPS/pH 7.2, 12.5 mM  $\beta$ -glycerophosphate, 25 mM MgCl<sub>2</sub>, 5 mM EGTA, 2 mM EDTA and 0.25 mM DTT) with 100  $\mu$ M ATP (Sigma) spiked with 0.74 MBq gamma-labeled ATP (20 nM)/reaction and 1  $\mu$ g recombinant ARTD1 fl., ARTD1 deletion fragments (ARTD1 fr.), HMGB1 or histone-mix (Roche) for 15 min. ARTD1 automodification assay contained PARP reaction buffer (50 mM Tris-HCl/pH 8, 4 mM

MgCl<sub>2</sub>, 250  $\mu$ M DTT, 1  $\mu$ g pepstatin/bestatin/leupeptin), 100  $\mu$ M or 100 nM unlabeled NAD (Sigma) spiked with 100 nM gamma-labeled NAD and in some cases 0.5 pmol of EcoRI dsDNA linker to induce ARTD1 activity *in vitro*.

### Evaluation of DNA damage

DNA damage (double-strand breaks, single-strand breaks, abasic sites) in cells was determined using the Alkaline Comet Assay (Trevigen) according to the manufacturer's instructions. %DNA in tail was calculated using Comet Assay IV (Perceptive Instruments).

## RESULTS

### H<sub>2</sub>O<sub>2</sub> rapidly induces nuclear PAR and in a cell cycle-independent manner

To study the signaling mechanisms by which oxidative stress induces PAR formation and to obtain kinetic and dose response information on this process, MRC-5 primary human fibroblasts were treated for various durations with increasing concentrations of H<sub>2</sub>O<sub>2</sub> (0.01–2 mM), and PAR formation was analyzed by immunofluorescence microscopy (Figure 1A and Supplementary Figure S1A). These experiments revealed that H<sub>2</sub>O<sub>2</sub> in a concentration-dependent manner transiently induced strong nuclear PAR formation already at 10 min after treatment, with levels returning to baseline after 60 min, and that maximum PAR formation was observed already at 0.1 mM H<sub>2</sub>O<sub>2</sub>. PAR formation coincided with activation of ARTD1, as shown by the automodification of ARTD1 in nuclei isolated from WT, but not ARTD1 knockout MEFs treated with H<sub>2</sub>O<sub>2</sub> for 10 min and incubated with radioactively labeled NAD<sup>+</sup> (Figure 1B). Moreover, knockdown of ARTD1 by siRNA confirmed that H<sub>2</sub>O<sub>2</sub>-induced PAR formation was predominantly mediated by ARTD1 (Figure 1C). To investigate the cell cycle stage dependency of H<sub>2</sub>O<sub>2</sub>-induced PAR formation, H<sub>2</sub>O<sub>2</sub>-treated MEFs were analyzed by quantitative image-based cell cycle staging. Nuclear PAR formation was induced by H<sub>2</sub>O<sub>2</sub> to the same extent in all cell cycle stages (Figure 1D and Supplementary Figure S1B), indicating cell cycle-independent ARTD1 activation. To investigate the early H<sub>2</sub>O<sub>2</sub>-induced signaling events under sub-lethal conditions, cell viability was assessed 24 h after treatment of cells with H<sub>2</sub>O<sub>2</sub>. The results revealed that H<sub>2</sub>O<sub>2</sub> at a concentration of

---

← extracts (NE) were prepared and 10  $\mu$ g were incubated with [<sup>32</sup>P]NAD in an *in vitro* ADP-ribosylation reaction for 15 min at 30°C. (C) PAR IF analysis of MRC-5 cells transfected with siRNA against ARTD1 or mock, and treated with 0.1 mM H<sub>2</sub>O<sub>2</sub> for 10 min or left untreated. Intensity (a.u.)  $\times 10^{-3}$ . (D) MEFs were incubated with EdU (10  $\mu$ M) for 15 min prior to 0.1 mM H<sub>2</sub>O<sub>2</sub> treatment for 10 min. Quantification of the mean PAR signal intensity per nucleus (a.u.) in G1, S and G2 cells ( $n = 4$ ). No significant (n.s.) difference in H<sub>2</sub>O<sub>2</sub>-induced PAR formation between the different cell cycle stages by *t*-test. (E) Work flow for characterization of H<sub>2</sub>O<sub>2</sub>-induced proteome changes by reverse phase protein microarrays (RPPA). MRC-5 cells were treated with 0.5 mM H<sub>2</sub>O<sub>2</sub>, cells lysed after 10 or 60 min and whole cell lysates (from biological duplicates) serially diluted and spotted on Zeptosens Chips in technical duplicates. Target-specific primary (see list of antibodies in Supplementary Data) and fluorophore-labeled secondary antibodies were incubated with the lysates. Microarray data were acquired using ZeptoREADER and ZeptoVIEW. (F) Time profile clustering of 0.5 mM H<sub>2</sub>O<sub>2</sub>-induced proteome changes in MRC-5 cells (ANOVA,  $n = 2$ ,  $P < 0.05$ ) analyzed by k-means algorithm as described in 'Material and Methods' section, showing increased protein expression/modification (green) or repression/de-modification (red). Modifications are indicated in brackets. In some cases, different antibodies (recognizing different epitopes of the same protein or protein modification) were applied in the screen. To differentiate these antibodies, a three digit number was included in the description. In some instances, the experiment was performed with the same antibody, e.g. p53 (phosphor-Ser15) (2-02) more than once, therefore the designation (2-02)<sub>3</sub> and <sub>4</sub>. The corresponding experiments <sub>1</sub> and <sub>2</sub> were excluded from the heat map, since they did not pass the stringent statistical analysis (ANOVA,  $n = 2$ ,  $P < 0.05$ ). (G) The data in panel F were plotted for each analyte in separate graphs grouped according to the cluster determined to better visualize the kinetic profile of the proteomic changes within each given group.

0.5 mM or below was sub-lethal under the tested condition (Supplementary Figure S1C).

### H<sub>2</sub>O<sub>2</sub> treatment induces dynamic proteomic changes

To investigate the early H<sub>2</sub>O<sub>2</sub>-induced signaling events that may regulate nuclear PAR formation, a proteomics screen using RPPA focusing on intracellular signaling cascades (i.e. kinases and their substrates) was performed on MRC-5 cells treated with a sublethal concentration of H<sub>2</sub>O<sub>2</sub> (i.e. 0.5 mM) for either 10 or 60 min, respectively (Figure 1E and F; Supplementary Figure S2A–D). The two different time-points were chosen because strong PAR formation was observed at 10 min, while PAR was no longer detectable at 60 min after H<sub>2</sub>O<sub>2</sub> treatment (Figure 1A and Supplementary Figure S1A). Significant changes in protein level or in post-translational modification in the RPPA analysis were determined by statistical analysis using ANOVA ( $P < 0.05$ ,  $n = 2$ ). Untreated samples were used as a control group (Figure 1F; Supplementary Figure S2A–D). The significant changes were clustered based on the temporal changes upon H<sub>2</sub>O<sub>2</sub> treatment, taking all time points into account, using k-means clustering algorithm (Figure 1G; Supplementary Figure S2A–D). The majority of significant signal reductions concerned total protein levels, while increases in response to H<sub>2</sub>O<sub>2</sub> treatment were often observed for phosphorylation events (Supplementary Figure S2D). Interestingly, early activation clusters 1–3 (10 min) comprised kinases exclusively found in the cytoplasm and known to be activated directly by either stress stimuli (p-p38, p-JNK) or growth factor signaling (ErbB-2, p-Akt). Ca<sup>2+</sup> signaling transducers were also found among the early-induced proteome changes (p-PLC $\gamma$ , p-PKC, p-CaMKII, p-CREB, p-PLA2) (Figure 1F and G; Supplementary Figure S2D). The majority of late activated signaling events (cluster 4, 60 min) included DNA damage response and cell cycle players such as p-aurora A, p-Chk1, p-cyclin D, p-p53, p-p27 and  $\gamma$ H2AX (Figure 1F and G). Downregulated protein or phosphorylation levels (cluster 5) included several factors involved in cell death. However, the main hubs (more  $\geq$  20 interactions) in the protein–protein interaction network (Akt, p38, ERK2) were rather cytoplasmic signaling components (except for p53) mostly induced at the early time point (10 min), indicating cytoplasmic signaling events as the initial signaling events upon sublethal H<sub>2</sub>O<sub>2</sub> (Supplementary Figure S2E). In summary, our systematic RPPA analyses of the early H<sub>2</sub>O<sub>2</sub>-induced proteome changes have identified several cytoplasmic signaling components. From the observed proteomic changes, the kinetics of several protein phosphorylations (e.g. of ERK1/2 and PKC substrates) strongly correlated with the kinetics of PAR formation, pointing at kinases as possible candidates that regulate PAR formation.


### Activation of membrane-associated phospholipase C and Ca<sup>2+</sup> signaling from the ER via IP3 are required for nuclear PAR formation

To further validate the H<sub>2</sub>O<sub>2</sub>-induced early signaling proteomic changes potentially responsible for PAR formation, a screen with small molecule inhibitors or siRNA

for a sub-set of the identified early-activated cytoplasmic kinases was performed. Thus, human IMR-90 or mouse NIH/3T3 fibroblasts were either treated with inhibitors for IKK, AMPK, p38, JNK or MEK, or with siRNA against these proteins, and H<sub>2</sub>O<sub>2</sub>-induced PAR formation assessed by IF analysis or western blotting using the 10H anti-PAR antibody (Supplementary Figure S3A–F). Although their H<sub>2</sub>O<sub>2</sub>-induced activation kinetics correlated with the enhanced PAR formation, pharmacological inhibition or knockdown/knockout of any of these kinases did not, or only weakly, affect H<sub>2</sub>O<sub>2</sub>-induced PAR levels, suggesting that the above-mentioned pathways do not regulate PAR formation. The investigation was therefore extended to additional pathways that were explored with small molecular inhibitors for their role in PAR formation. One of the earliest changes observed by the RPPA (10 min) was enhanced phosphorylation of membrane-associated phospholipase C (PLC $\gamma$ ) (Figure 1F). To investigate a possible involvement of PLC $\gamma$  in H<sub>2</sub>O<sub>2</sub>-induced PAR formation, IMR-90 fibroblasts were treated with the PLC inhibitor (PLCi) U-73122 (Figure 2A). Treatment of cells with PLCi before H<sub>2</sub>O<sub>2</sub> treatment significantly reduced PAR formation, revealing that PLC contributes to PAR formation. PLC is known to stimulate the inositol triphosphate receptor (IP3R) at the ER through the synthesis of IP3. Thus, to determine whether this pathway is important for H<sub>2</sub>O<sub>2</sub>-induced PAR formation, IMR-90 fibroblasts were pre-incubated with IP3R inhibitor 2-APB (IP3Ri), which also led to significantly reduced H<sub>2</sub>O<sub>2</sub>-induced PAR formation. Importantly, the knockdown of PLC $\gamma$  or IP3R by siRNA-mediated knockdown led to a very strong reduction in H<sub>2</sub>O<sub>2</sub>-induced PAR formation in NIH/3T3 fibroblasts (Figure 2B and Supplementary Figure S4A). Together, these results support the notion that PLC induces a signaling cascade through IP3 and subsequent stimulation of the IP3R at the ER membrane for the induction of PAR formation. Activation of IP3R is known to release Ca<sup>2+</sup> from the ER. To investigate the role of Ca<sup>2+</sup>-signaling in H<sub>2</sub>O<sub>2</sub>-induced PAR formation, cells were pre-treated with the cell membrane-permeable intracellular Ca<sup>2+</sup> chelator BAPTA-AM (Ca<sup>2+</sup><sub>che</sub>). Indeed, pre-treatment of cells with BAPTA-AM significantly reduced H<sub>2</sub>O<sub>2</sub>-induced PAR formation assessed by immunofluorescence microscopy or immunoblot analysis (Figure 2A and Supplementary Figure S4B), indicating that Ca<sup>2+</sup> signaling positively regulates PAR formation. Moreover, to rule out any cell cycle-specific Ca<sup>2+</sup>-dependency, H<sub>2</sub>O<sub>2</sub>-induced PAR formation in MEFs pre-incubated with BAPTA-AM were analyzed using quantitative image-based cell cycle staging. BAPTA-AM significantly inhibited nuclear PAR formation in all cell cycle phases, indicating that the Ca<sup>2+</sup>-dependency of PAR formation is cell cycle-independent (Figure 2C). BAPTA-AM did not block the very weak but detectable basal PAR levels in untreated cells, suggesting that basal PAR formation is not dependent on Ca<sup>2+</sup> (Supplementary Figure S4C).

### PKC $\alpha$ controls H<sub>2</sub>O<sub>2</sub>-induced PAR formation

An early-altered potential downstream component observed in the RPPA analysis of the identified Ca<sup>2+</sup>-dependent signaling cascade, was the phosphorylation of



**Figure 2.** Negative and positive modulation of ARTD1 activity by different PKC family members. (A) PAR IF analysis of IMR-90 pre-incubated with selected inhibitors or DMSO (control) prior to 0.1 mM H<sub>2</sub>O<sub>2</sub> treatment for 10 min, or left untreated. Inhibitors against Ca<sup>2+</sup> (BAPTA-AM, 10 μM),

PKC substrates. The PKC family of protein kinases consists of the conventional,  $\text{Ca}^{2+}$ -dependent enzymes, as well as the novel and atypical  $\text{Ca}^{2+}$ -independent kinases (59). In mammals, the PKC protein family consists of four conventional (PKC $\alpha$ , - $\beta$ I/II and - $\gamma$ ), four novel (PKC $\delta$ , - $\epsilon$ , - $\eta$  and - $\theta$ ) and two atypical (PKC $\zeta$  and - $\nu$ ) isozymes (59). To investigate whether early-activated PKCs are involved in  $\text{H}_2\text{O}_2$ -induced PAR formation, MRC-5 cells were pre-incubated with the PKC pan inhibitor GF109203X (PKCi), which targets all isoforms. Interestingly, pan inhibition of PKCs led to enhanced  $\text{H}_2\text{O}_2$ -induced PAR formation (Figure 2D). Similar results were obtained with IMR-90 cells (Supplementary Figure S4D). However, the PKCi-mediated enhancement of  $\text{H}_2\text{O}_2$ -induced PAR formation was completely abolished by the  $\text{Ca}^{2+}$  chelator BAPTA-AM ( $\text{Ca}^{2+}_{\text{che}}$ ), suggesting that  $\text{Ca}^{2+}$ -dependent signaling dominates the negative regulatory effect mediated by PKC. To confirm PKC-dependent regulation of  $\text{H}_2\text{O}_2$ -induced PAR formation, MRC-5 cells were transfected with a pan siPKC against all PKC family members. In contrast to the PKC inhibitor effect, knockdown of PKC isoforms, including PKC $\alpha$  and PKC $\delta$ , led to a strong reduction in  $\text{H}_2\text{O}_2$ -induced PAR formation (Figure 2E and F), suggesting that different PKC family members may regulate PAR formation in opposing ways. Thus, to dissect the positive and negative regulatory effects observed by PKC inhibition and downregulation, NIH/3T3 cells were transfected with siPKC $\alpha$  and/or siPKC $\delta$ . In line with the PAR-reducing effect of BAPTA-AM, knockdown of the  $\text{Ca}^{2+}$ -dependent isoform PKC $\alpha$  resulted in significantly lower  $\text{H}_2\text{O}_2$ -induced PAR formation as compared to control siRNA (Figure 2G and Supplementary Figure S4E). This effect was confirmed using PKC $\alpha$  knockout MEFs, which showed significantly less  $\text{H}_2\text{O}_2$ -induced PAR formation as compared to WT MEF (Supplementary Figure S4F and G). In contrast, knockdown of the  $\text{Ca}^{2+}$ -independent isoform PKC $\delta$  resulted in enhanced PAR formation, comparable to that with the pan PKC inhibitor. Double knockdown of PKC $\alpha$  and PKC $\delta$  caused a reduction in PAR levels similar to that by knockdown of PKC $\alpha$  only, suggesting a dominant effect of PKC $\alpha$  over PKC $\delta$  on PAR formation (Figure 2G). Knockdown of the conventional PKC family members  $\beta$  and  $\gamma$  showed no effect on PAR formation (Supplementary Figure S4H). Together, these results demonstrate that while PKC $\delta$  rather attenuates  $\text{H}_2\text{O}_2$ -induced PAR formation, PKC $\alpha$  is required for  $\text{H}_2\text{O}_2$ -induced PAR formation.

To further investigate the positive regulatory function of PKC $\alpha$  in  $\text{H}_2\text{O}_2$ -induced PAR formation and whether PKC $\alpha$  translocates to the nucleus in response to  $\text{H}_2\text{O}_2$  to


potentially regulate ARTD1 activity in this compartment, a nuclear/cytoplasmic separation of  $\text{H}_2\text{O}_2$ -treated MEFs was performed. Analysis of PKC $\alpha$  localization by immunoblotting showed that indeed 10 min after treatment of MEFs with  $\text{H}_2\text{O}_2$ , PKC $\alpha$  levels were  $\sim 2.5$ -fold increased in the nucleus, with a corresponding decrease in the cytoplasm (Figure 3A), suggesting that upon  $\text{H}_2\text{O}_2$  treatment a part of PKC $\alpha$  translocates to the nucleus.

### **$\text{Ca}^{2+}$ -signaling induces DNA damage that is neither dependent on PKC $\alpha$ , OGG1 nor APE1**

ARTD1 has been described to be activated by DNA damage (60). To confirm that the zinc fingers of ARTD1 are required for  $\text{H}_2\text{O}_2$ -induced PAR formation, ARTD1 knockout fibroblasts were genetically complemented with a mutant lacking zinc fingers 1 and 2, or a mutant lacking PAR forming activity (E988K). The results of these experiments revealed that the presence of zinc fingers and thus the binding to DNA is important for the ARTD1-mediated PAR formation *in vivo* (Supplementary Figure S5A). Interestingly,  $\text{H}_2\text{O}_2$ -induced PAR formation did not coincide with an increase in  $\gamma\text{H2A.X}$  staining, which was observed only after 30 min, or 53BP1 foci formation, for which no increase could be observed within 60 min of  $\text{H}_2\text{O}_2$  treatment (Supplementary Figure S5B). However,  $\text{H}_2\text{O}_2$  in a dose and time-dependent manner did induce DNA damage as measured by DNA tail formation using the alkaline comet assay (Supplementary Figure S5C). Since ARTD1 is strongly activated by DNA damage, we tested whether PKC $\alpha$ -dependent signaling is responsible for the induction of the observed DNA damage and activation of ARTD1. MEF cells were treated with siPKC $\alpha$ , stimulated with  $\text{H}_2\text{O}_2$  and DNA integrity assessed by the alkaline comet assay.  $\text{H}_2\text{O}_2$  induced DNA tail formation comparably in cells treated with siPKC $\alpha$  or siMock (Figure 3B), suggesting that PKC $\alpha$  does not regulate PAR formation by affecting  $\text{H}_2\text{O}_2$ -induced DNA damage. Similarly,  $\text{H}_2\text{O}_2$ -induced activation of ARTD1 measured by automodification activity in nuclear extracts (NE) was not affected by siPKC $\alpha$  treatment (Figure 3C). Thus, since PAR formation was completely abrogated upon knockdown of PKC $\alpha$ , these experiments provide evidence that the induced DNA damage seems to be required but not sufficient to induce PAR formation by ARTD1. Intriguingly, treatment of cells with BAPTA-AM caused a marked reduction in  $\text{H}_2\text{O}_2$ -induced DNA tail formation (Figure 3D) and activation of ARTD1 (Figure 3E), suggesting that  $\text{Ca}^{2+}$ -dependent signaling is important both for the observed DNA tail formation and ARTD1 activation. Interestingly, neither knockdown of the

IP3R (2-APB, 100  $\mu\text{M}$ ), PLC (U-73122, 1  $\mu\text{M}$ ). Quantification of 10–20 nuclei analyzed per area ( $n = 10$ ), intensity in arbitrary units  $\times 10^{-5}$ . (B) PAR IF analysis of NIH/3T3 upon treatment with 0.1 mM  $\text{H}_2\text{O}_2$  for 10 min 48 h after siRNA transfection. Quantification of 20–40 nuclei analyzed per area ( $n = 3$ ). (C) MEFs pre-treated with 10  $\mu\text{M}$  BAPTA-AM or DMSO were incubated with EdU (10  $\mu\text{M}$ ) for 15 min, stimulated for 10 min with  $\text{H}_2\text{O}_2$  (0.1 mM), before fixation and staining. Quantification of the mean PAR signal intensity per nucleus in G1, S and G2 cells, displayed as arbitrary units,  $n = 4$ . (D) PAR IF analysis of MRC-5 pre-incubated with 5  $\mu\text{M}$  GF109203X (PKC inhibitor) or 10  $\mu\text{M}$  BAPTA-AM ( $\text{Ca}^{2+}$  chelator) or left untreated (U) prior to 0.1 mM  $\text{H}_2\text{O}_2$  for 10 min. Intensity in arbitrary units  $\times 10^{-5}$ . (E) PAR IF staining of MRC-5 cells transfected with siPKC (pan) prior to  $\text{H}_2\text{O}_2$  treatment for 10 min (left). Quantification of PAR IF staining of MRC-5 cells transfected with siPKC (pan) prior to  $\text{H}_2\text{O}_2$  treatment for 10 min (10–20 cells/condition,  $n = 5$ ) (right). (F) Knockdown efficiency in e) was confirmed by immunoblotting with anti-ARTD1, anti-PKC $\alpha$  or anti-PKC $\delta$  using anti-tubulin as loading control. (G) PAR IF analysis of NIH/3T3 cells transfected with siPKC $\alpha$  and/or siPKC $\delta$ , siARTD1 (positive ctrl) or siMock (negative control) prior to  $\text{H}_2\text{O}_2$  (0.1 mM) treatment for 10 min (500 cells/condition,  $n = 2$ ). Data represent mean  $\pm$  SD analyzed by *t*-test with \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , n.s. not significant.





**Figure 3.** PKC $\alpha$  regulates PAR formation in a DNA break-independent manner. **(A)** MEFs pre-treated with 10  $\mu$ M olaparib or left untreated prior to 0.5 mM H<sub>2</sub>O<sub>2</sub> treatment for 10 min. Nuclear and cytoplasmic extracts were analyzed by immunoblotting. Quantification of PKC $\alpha$  levels was performed by densitometry, normalizing nuclear levels to ARTD1 and cytoplasmic levels to tubulin. **(B)** Alkaline comet assay of siPKC $\alpha$  transfected MEFs or siMock (negative control) prior to 0.1 mM H<sub>2</sub>O<sub>2</sub> treatment for 10 min (100 nuclei analyzed/independent experiment,  $n = 2$ ). **(C)** MEFs transfected with siPKC $\alpha$  or siMock were treated with 0.5 mM H<sub>2</sub>O<sub>2</sub> for 10 min. NE were prepared and 10  $\mu$ g incubated in an *in vitro* ADP-ribosylation assay using NAD (<sup>32</sup>P) in the presence or absence of recombinant PKC $\alpha$  for 15 min at 30°C. Loading controlled by Coomassie blue (CB) staining of the gel (lower panel). **(D)** Alkaline comet assay of MEFs pre-treated with 10  $\mu$ M BAPTA-AM (Ca<sup>2+</sup><sub>che</sub>) for 30 min or left untreated prior to 0.1 mM H<sub>2</sub>O<sub>2</sub> treatment for 10 min (100 nuclei analyzed/independent experiment,  $n = 3$ ). **(E)** MEFs were pre-incubated with either 10  $\mu$ M olaparib, 10  $\mu$ M BAPTA-AM or left untreated prior to 0.5 mM H<sub>2</sub>O<sub>2</sub> for 10 min. NE were prepared and 10  $\mu$ g incubated in an *in vitro* ADP-ribosylation assay using NAD (<sup>32</sup>P) in the presence or absence of BAPTA-AM for 15 min at 30°C. **(F)** Alkaline comet assay of NIH/3T3 cells pre-incubated with BAPTA (20  $\mu$ M) or DMSO prior to KBrO<sub>3</sub> (30 mM, 1 h) or MNNG (50  $\mu$ M, 1 h) treatment (50 nuclei analyzed/independent experiment,  $n = 6$ ). **(G)** PKC $\alpha$  kinase assay using ARTD1 full length and Pol  $\beta$  (positive control) as substrates and radiolabeled ATP (<sup>32</sup>P). **(H)** PKC $\alpha$  kinase assay using ARTD1 deletion fragments or full length ARTD1 as substrate and radiolabeled ATP (<sup>32</sup>P). **(I)** ADP-ribosylation assay using radiolabeled NAD (<sup>32</sup>P). PKC $\alpha$  was pre-incubated with ATP and/or ARTD1 for 30 min before adding PKC inhibitor (GF109203X, 5  $\mu$ M), NAD (<sup>32</sup>P) and 5, 0.5, 0.05, 0.005 or 0 pmol of EcoRI linker (ds DNA) and incubated for 15 min at 30°C. Data in bar graphs represent mean  $\pm$  SD analyzed by *t*-test with \* $P < 0.05$ , \*\* $P < 0.01$ , n.s. not significant.

$\text{Ca}^{2+}$ -dependent DNA-glycosylase OGG1 nor APE1 affected PAR formation or induced DNA tail formation after 10 min of  $\text{H}_2\text{O}_2$  (Supplementary Figure S5D–F), suggesting that the observed DNA damage may not be 8oxoG DNA modifications or abasic sites. To investigate whether the dependency on  $\text{Ca}^{2+}$  was specific for  $\text{H}_2\text{O}_2$ -induced DNA tail formation, 3T3 cells were treated for 1 h with  $\text{KBrO}_3$  or MNNG, after pre-incubation with BAPTA-AM or DMSO. The DNA damage induced by these agents was either not ( $\text{KBrO}_3$ ) or only moderately affected (MNNG) by treatment with BAPTA-AM, suggesting that the dependency on  $\text{Ca}^{2+}$  is particularly specific for  $\text{H}_2\text{O}_2$ -induced DNA tail formation and that  $\text{H}_2\text{O}_2$  induces DNA damage by an as yet unidentified  $\text{Ca}^{2+}$ -dependent mechanism (Figure 3F).

### PKC $\alpha$ -mediated phosphorylation of ARTD1, histones or HMGB1 do not directly regulate ARTD1 enzymatic activity *in vitro*

Since PKC $\alpha$  was observed to translocate to the nucleus (Figure 3A) and to assess a direct regulation of ARTD1 activity through phosphorylation by PKC $\alpha$  in the nucleus, full-length ARTD1 was incubated with PKC $\alpha$  and radioactively labeled ATP *in vitro*. DNA polymerase beta (Pol $\beta$ ), known to be phosphorylated by PKC (61) was included as positive control in the reaction containing PKC $\alpha$  (Figure 3G). A radioactive modification was detected for ARTD1 in the presence of PKC $\alpha$ , indicating that PKC $\alpha$  is able to directly phosphorylate ARTD1 *in vitro*. To narrow down the ARTD1 phosphorylation site, different ARTD1 fragments were tested to be modified by PKC $\alpha$ . All tested fragments were phosphorylated by PKC $\alpha$ , although to a different extent, indicating that ARTD1 is phosphorylated indiscriminately at various sites across the whole protein (Figure 3H). To assess whether the enzymatic activity of ARTD1 is affected by PKC $\alpha$ -mediated phosphorylation, ARTD1 pre-incubated with PKC $\alpha$  in the presence or absence of ATP was subsequently incubated with radioactively labeled  $\text{NAD}^+$  and different amounts of DNA (Figure 3I). ARTD1 activity was essentially the same whether ARTD1 was pre-phosphorylated by PKC $\alpha$  or not, thus excluding direct PKC $\alpha$ -dependent phosphorylation of ARTD1 as the mechanism by which PAR formation is induced in a  $\text{Ca}^{2+}$ -dependent manner upon  $\text{H}_2\text{O}_2$  treatment and suggest an indirect mechanism by which PKC $\alpha$  activates ARTD1. Interestingly, comparable experiments with the  $\text{Ca}^{2+}$ -independent PKC $\delta$  isoform revealed that PKC $\delta$  phosphorylates ARTD1 at the N-terminus (amino acids 1–214) and phosphorylation of ARTD1 by PKC $\delta$  inhibited DNA-induced PAR formation by ARTD1 *in vitro* (Supplementary Figure S6A and S6B), suggesting that the observed stimulatory effect of the PKC $\alpha$  on PAR formation might be due to inhibition of ARTD1 by PKC $\delta$ .

Considering that PKC $\alpha$  does neither influence ARTD1 activity *in vitro* nor in NE, but in the nucleus on the chromatin, other chromatin-associated PKC $\alpha$  targets could potentially positively influence PAR formation. To study the consequences of histone phosphorylation by PKC $\alpha$ , recombinant histones were incubated with PKC $\alpha$  and radioactively labeled ATP. A signal corresponding to phosphorylated core histones was observed, but showed no enhance-


ing effect on ARTD1 autocatalytic activity, neither in the phosphorylated nor the non-phosphorylated state (Supplementary Figure S6C and D), indicating that PKC $\alpha$  does not mediate PAR formation by the phosphorylation of histones.

Another known PKC $\alpha$  target within the chromatin landscape that could potentially affect PAR formation is the ubiquitously expressed histone-like protein high mobility-group protein box 1 (HMGB1). To study the consequences of HMGB1 phosphorylation by PKC $\alpha$ , recombinant HMGB1 was incubated with PKC $\alpha$  and radioactively labeled ATP. A strong signal corresponding to phosphorylated HMGB1 was observed (Supplementary Figure S6E), confirming that HMGB1 is a target of PKC $\alpha$  *in vitro*. However, neither phosphorylated nor non-phosphorylated HMGB1 showed any influence on ARTD1 autocatalytic activity *in vitro* (Supplementary Figure S6F), suggesting that HMGB1 does not directly influence ARTD1 activity in a simple *in vitro* setting. However, these *in vitro* studies are not in the context of the nucleus and chromatin, which could be an important factor for the activity of ARTD1 and its potential modulation by HMGB1.

### Chromatin-associated HMGB1 represses PAR formation *in vivo* and is evicted upon $\text{H}_2\text{O}_2$ treatment in a PKC $\alpha$ -dependent manner

Since PKC-mediated phosphorylation of HMGB1 has been described to alter its DNA binding-affinity, as well as nuclear localization (29,62,63), we knocked down HMGB1 together with PKC $\alpha$  in WT MEF cells to further investigate a possible contribution of HMGB1 to PAR formation. Interestingly, knockdown of HMGB1 alone already enhanced  $\text{H}_2\text{O}_2$ -induced PAR formation, suggesting that the presence of HMGB1 represses PAR formation. Interestingly, double knockdown of HMGB1 and PKC $\alpha$  reversed the inhibitory effect of PKC $\alpha$  single knockdown on  $\text{H}_2\text{O}_2$ -induced PAR formation (Figure 4A and Supplementary Figure S6G). In HMGB1 knockout MEFs, the inhibitory effect on PAR formation by PKC $\alpha$  knockdown was also greatly attenuated (Figure 4B). This suggests that the presence of HMGB1 has an inhibitory effect on PAR formation, which is relieved by PKC $\alpha$ , thereby making PKC $\alpha$  a requirement for PAR formation upon  $\text{H}_2\text{O}_2$  stimulation. To test whether the rescued PAR formation in PKC $\alpha$ /HMGB1 double knockdown MEFs is also dependent on  $\text{Ca}^{2+}$  signaling-induced DNA damage, MEFs were treated with BAPTA-AM after knockdown of HMGB1 alone or after HMGB1/PKC $\alpha$  double-knockdown (which showed the partial rescue) and PAR formation assessed after  $\text{H}_2\text{O}_2$  treatment (Figure 4A and B). BAPTA-AM abrogated PAR formation also under these tested conditions, suggesting that  $\text{Ca}^{2+}$ -dependent DNA damage is an important initiation step for  $\text{H}_2\text{O}_2$ -induced PAR formation.

To investigate whether HMGB1 also contributes to the effect of PKC $\alpha$  knockdown in human cells (cf. Figure 2E), the effect of PKC $\alpha$  knockdown (using siPKC) was tested in MRC-5 cells knocked-down for HMGB1 and compared to cells with proficient HMGB1 levels (Figure 4C and Supplementary Figure S6H). Also in this case, the attenuating effect of PKC $\alpha$  knockdown on PAR formation was reversed in cells depleted of HMGB1. These results provide strong



**Figure 4.** PKC $\alpha$ -dependent phosphorylation of HMGB1 is required for H<sub>2</sub>O<sub>2</sub>-induced PAR formation. (A) MEFs treated with scrambled siRNA or siRNA against HMGB1 and/or PKC $\alpha$  were incubated 10 min with 0.5 mM H<sub>2</sub>O<sub>2</sub>, in the absence or presence of BAPTA-AM (Ca<sup>2+</sup><sub>che</sub>) and stained for PAR (left). Quantification of PAR intensity (right), 200 nuclei analyzed/experiment,  $n = 3$ . (B) HMGB1 knockout MEFs treated with scrambled siRNA or siRNA against PKC $\alpha$  were pretreated with 10  $\mu$ M BAPTA-AM or left untreated, before 10 min treatment with 0.5 mM H<sub>2</sub>O<sub>2</sub> and stained for PAR. Quantification of PAR intensity (right), 200 nuclei analyzed/experiment,  $n = 3$ . (C) Quantification of PAR intensity in MRC-5 cells treated with scrambled siRNA or siRNA against HMGB1 and/or PKC (pan), stained for PAR after 10 min of 0.5 mM H<sub>2</sub>O<sub>2</sub> treatment (20 nuclei analyzed,  $n = 5$ ). (D) Immunofluorescence analysis of nuclear HMGB1 in MEFs transfected with scrambled siRNA or siRNA against PKC $\alpha$  (left), or pretreated with 10  $\mu$ M olaparib or DMSO (right), and treated with 0.5 mM H<sub>2</sub>O<sub>2</sub> for 10 min, or left untreated. Data are mean  $\pm$  SD analyzed by t-test with \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , n.s. not significant.

evidence that the positive effect of PKC $\alpha$  on PAR formation is mediated in large parts through HMGB1 and that the effect is conserved.

To confirm that PKC $\alpha$  indeed also affects the chromatin association and cellular localization of HMGB1 upon H<sub>2</sub>O<sub>2</sub> treatment, the nuclear levels of HMGB1 in H<sub>2</sub>O<sub>2</sub>-treated MEFs were examined by immunofluorescence. While decreased nuclear levels of HMGB1 could be detected in H<sub>2</sub>O<sub>2</sub>-treated as compared to non-treated MEFs, the nuclear levels of HMGB1 in MEFs with knocked down PKC $\alpha$  remained unaffected (Figure 4D), indicating that PKC $\alpha$  reduces HMGB1 nuclear levels. It has been reported that ARTD1 and PAR formation is important for the re-

lease of HMGB1 from the nucleus upon certain stimuli (64,65). However, the nuclear reduction of HMGB1 upon 10 min H<sub>2</sub>O<sub>2</sub> treatment was not due to HMGB1 ADP-ribosylation, since inhibition of PAR formation by olaparib did not affect the HMGB1 levels (Figure 4D), suggesting that not PARylation by ARTD1, but rather PKC $\alpha$  is important for the reduction of nuclear HMGB1 levels upon 10 min H<sub>2</sub>O<sub>2</sub> treatment.

## DISCUSSION

Our results indicate that H<sub>2</sub>O<sub>2</sub> causes ARTD1-mediated PAR formation by inducing intracellular Ca<sup>2+</sup> through

PLC-generated IP<sub>3</sub>. Increased Ca<sup>2+</sup> then increases PAR formation by two main molecular mechanisms: DNA damage and activation/nuclear translocation of PKC $\alpha$ , which induces chromatin eviction of HMGB1 to successfully induce full PAR formation in the nucleus (Figure 5).


H<sub>2</sub>O<sub>2</sub>-induced oxidative stress is a potent activator of nuclear PAR formation in different cell types, but a coherent picture of the molecular events that lead to ARTD1 activation and PAR formation has not existed so far. Although ARTD1 was suggested to be activated upon H<sub>2</sub>O<sub>2</sub> treatment via the induction of oxidative DNA damage, a mechanism providing evidences for such a direct activation *in vivo* has not been reported previously and ample evidence suggests additional possibilities of controlling ARTD1 enzymatic activity, such as through phosphorylation of ARTD1 or the interaction with modified histones (22,34,35). To elucidate the signaling pathways activated during H<sub>2</sub>O<sub>2</sub>-induced oxidative stress, we applied a proteomics screen using RPPA focusing on the major intracellular signaling cascades (i.e. kinases and their substrates) in MRC-5 cells treated with a sublethal concentration of H<sub>2</sub>O<sub>2</sub>. Overall, H<sub>2</sub>O<sub>2</sub> treatment principally caused decreases in protein signaling by diminishing total protein level, while producing increases in protein phosphorylation. This could be explained by H<sub>2</sub>O<sub>2</sub>-induced inhibition of translation, which causes a general reduction of the protein half-life (66). Moreover, this analysis revealed the kinetics of the H<sub>2</sub>O<sub>2</sub>-mediated activation of several pathways. The bioinformatics analysis of the samples treated with 0.5 mM did not significantly differ from samples treated with a lethal dose (i.e. 2 mM, data not shown), suggesting that the initiated signal pathways are the same, independent on the cell fate. Interestingly, validation of several pathways with inhibitors and siRNA revealed that many of the induced pathways did not, or only weakly, affect PAR formation, suggesting that these pathways do not regulate nuclear PAR formation. However, knockdown of PKC $\alpha$  significantly inhibited H<sub>2</sub>O<sub>2</sub>-induced PAR formation.

Signaling events upstream of PKC $\alpha$ , including Ca<sup>2+</sup> release from the endoplasmic reticulum and Ca<sup>2+</sup>-dependent signaling were confirmed to play a major role in H<sub>2</sub>O<sub>2</sub>-induced PAR formation. Interestingly, BAPTA-AM showed no effect on the PAR levels in untreated cells, suggesting that basal PAR formation is not dependent on Ca<sup>2+</sup>. Whether other PAR-inducing conditions depend on PKC $\alpha$  has to be further investigated. This finding is in agreement with studies that have implicated Ca<sup>2+</sup> signaling in the activation of ARTD1 (67–69). Our findings revealed that Ca<sup>2+</sup> release is initiated at the cellular plasma membrane through phospholipase C (PLC)-mediated signaling. This is in agreement with earlier publications reporting that phosphorylation and activation of PLC by a sulfhydryl oxidation-dependent mechanisms, which leads to increased IP<sub>3</sub> synthesis and subsequent activation of the IP<sub>3</sub> receptor, inducing the release of Ca<sup>2+</sup> from intracellular stores (70,71). In addition, H<sub>2</sub>O<sub>2</sub> treatment has also been reported to inactivate PTEN, which in turn increases cellular IP<sub>3</sub> concentration (72). H<sub>2</sub>O<sub>2</sub>-induced Ca<sup>2+</sup> mainly activated two different molecular processes that regulate nuclear PAR formation: the induction of DNA damage and

the activation of PKC $\alpha$ , respectively. The exact nature of the observed Ca<sup>2+</sup>-induced DNA damage needs further investigation, since the comet assay used in these experiments detects both double-strand, and single-strand DNA breaks, and also abasic sites. Although we did observe a very strong correlation between Ca<sup>2+</sup> release and the induction of DNA damage, we cannot assess the extent to which the induced DNA damage is required for PAR formation, since the molecular mechanism responsible for the induction of the observed damage is currently not known. Interestingly, neither knockdown of OGG1 nor APE1 affected PAR formation or DNA damage 10 min after H<sub>2</sub>O<sub>2</sub>, suggesting that the initial H<sub>2</sub>O<sub>2</sub>-induced DNA damage may not be at 8oxoG or abasic DNA sites. Importantly, since PAR formation but not DNA damage was completely abrogated upon knockdown of PKC $\alpha$ , DNA damage itself is required but not sufficient to induce PAR formation upon H<sub>2</sub>O<sub>2</sub> treatment.

Ca<sup>2+</sup> also activated the Ca<sup>2+</sup>-dependent PKC isoform PKC $\alpha$ , which upon H<sub>2</sub>O<sub>2</sub>-treatment translocated to the nucleus. Interestingly, PKC $\alpha$  has so far not been linked to the regulation of PAR metabolism and ARTD1 activity and was only studied as a factor affected by PARP inhibition (73). We found that PKC $\alpha$  was able to phosphorylate ARTD1, as previously shown for both PKC $\alpha$  and PKC $\beta$  (74). However, phosphorylation of ARTD1 by PKC $\alpha$  *in vitro* did not alter ARTD1 enzymatic activity. In contrast, H<sub>2</sub>O<sub>2</sub> treatment also activated the Ca<sup>2+</sup> independent PKC isoform PKC $\delta$ , which phosphorylated ARTD1 *in vitro* and reduced ARTD1-dependent DNA-induced PAR formation. This observation is in agreement with the data showing that inhibition of PKC signaling by the pan PKC inhibitor GF109203X led to a significant increase in H<sub>2</sub>O<sub>2</sub>-induced PAR formation. Indeed, PKC has been previously shown to phosphorylate ARTD1 *in vitro* (38) and its inhibition resulted in increased PAR induction upon alkylation stress (37), while there are also studies that have reported a positive regulation of ARTD1 by PKC $\delta$  in response to histamine (39,75). Thus, reported studies so far have identified two seemingly opposing (positively and negatively), Ca<sup>2+</sup>-dependent and -independent regulatory mechanisms for PAR formation upon H<sub>2</sub>O<sub>2</sub>-induced oxidative stress within the PKC family of proteins in human primary fibroblasts as well as in murine NIH/3T3 cells and MEFs. However, since the double knockdown of PKC $\alpha$  and PKC $\delta$  in our studies reduced PAR levels in the analyzed human and mouse fibroblast similar to that by knockdown of PKC $\alpha$  only, PKC $\alpha$  seems to play the dominant and more relevant role in PAR formation in the analyzed cell types.

H<sub>2</sub>O<sub>2</sub> treatment of cells has been described to influence the chromatin structure, possibly dependent on Ca<sup>2+</sup> signaling (76). The release of HMGB1 from chromatin and its translocation from the nucleus into the cytoplasm is inhibited by Ca<sup>2+</sup> chelation (77), showing the importance of Ca<sup>2+</sup> signaling in HMGB1 dissociation from chromatin. In HMGB1-deficient cells, we observed a stronger PAR formation in response to H<sub>2</sub>O<sub>2</sub>. Thus, there is a growing body of evidence that cellular signaling and chromatin-associated changes are involved in the activation of ARTD1 in a DNA damage-independent manner (78). These results suggest that the presence of HMGB1 in the nucleus represses PAR formation during H<sub>2</sub>O<sub>2</sub>-induced DNA damage, until the



**Figure 5.** Schematic representation of the signaling pathways involved in  $\text{H}_2\text{O}_2$ -induced PAR formation. ARTD1 is activated by  $\text{Ca}^{2+}$  by two different mechanisms: (i)  $\text{Ca}^{2+}$ -dependent formation of DNA strand breaks, as indicated by the curved dashed arrow and yellow star on the DNA and (ii)  $\text{PKC}\alpha$  activation, translocation to the nucleus and subsequent reduction of nuclear HMGB1 (straight dashed arrow), which releases the repression of ARTD1.

$\text{H}_2\text{O}_2$ -stimulated  $\text{Ca}^{2+}$  release activates  $\text{PKC}\alpha$ . This leads to decreased affinity of HMGB1 to the chromatin and subsequent nuclear release, revealing an intriguing interplay between PAR-stimulating and inhibiting mechanisms. We provide here evidence that  $\text{PKC}\alpha$  interacts and phosphorylates HMGB1 *in vitro*, and likely the phosphorylation of HMGB1 or of other factors associated with HMGB1, leads to the reduction of HMGB1 protein levels in the nucleus. HMGB1 is known as an inflammatory signaling protein (79,80). Whether the reduction of HMGB1 in the nucleus is due to translocation to the cytosol and extracellular space or due to degradation, remains to be elucidated. Unfortunately, due to lack of phospho-specific HMGB1 antibodies and the transient nature of the interaction, several attempts with commercially available Ser/Thr phosphorylation antibodies and co-immunoprecipitation failed to confirm the phosphorylation of HMGB1 *in vivo* or the interaction of  $\text{PKC}\alpha$  with HMGB1 in an  $\text{H}_2\text{O}_2$ -dependent manner (data not shown). Since the phosphorylation of HMGB1 has also been suggested to affect its DNA binding affinity (62), its phosphorylation and effect on PAR formation could potentially also involve a change in DNA-binding and chromatin association. It has been suggested that PAR formation is important for the release of HMGB1 from the nucleus into the cytoplasm upon stress signaling, such as induced by LPS or MNNG (64,65,81). However, pre-incubation of cells with PARPi does not affect the nuclear levels of HMGB1 after 10 min of  $\text{H}_2\text{O}_2$  treatment, suggesting that the release is phosphorylation-dependent, but ADP-ribosylation-independent. Interestingly, the regu-

latory effect of  $\text{PKC}\alpha$  on PAR formation was strongly reduced in cells lacking HMGB1, suggesting that HMGB1 is the principle, although may not be the only  $\text{PKC}\alpha$  target involved in controlling PAR formation. The impact of HMGB1 release on the chromatin structure, which chromatin domains (e.g. eu- or heterochromatin) are mainly affected, and how the release allows for PAR formation needs further investigation. Whether the derepression of ARTD1 activity, due to  $\text{Ca}^{2+}$ -induced  $\text{PKC}\alpha$ -dependent HMGB1 chromatin release includes additional proteins (e.g. H1 or HP1) or  $\text{Ca}^{2+}$ -dependent processes *in vivo* remains to be determined.

In summary, our findings have identified the key players that determine  $\text{H}_2\text{O}_2$ -induced nuclear PAR formation, which involves parallel  $\text{Ca}^{2+}$ -dependent signaling pathways: apart from  $\text{Ca}^{2+}$ -induced DNA damage, the  $\text{Ca}^{2+}$ -dependent activation of  $\text{PKC}\alpha$  leads to its nuclear translocation, and subsequently, the eviction of HMGB1 from chromatin, allowing full PAR formation to take place. These results thus identify  $\text{PKC}\alpha$  and HMGB1 as important regulators of the chromatin modulation involved in  $\text{H}_2\text{O}_2$ -induced PAR formation, a finding that may have important medical relevance for oxidative stress-associated pathophysiological conditions.

#### SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

## ACKNOWLEDGEMENTS

We are grateful to Roger Davies (University of Massachusetts Medical School) for providing JNK1/2 WT and JNK1/2<sup>-/-</sup> MEFs, Peter J. Parker (Francis Crick Institute, UK) for PKC $\alpha$  knockout MEFs and Marco E. Bianchi (San Raffaele University, Milano, Italy) for immortalized HMGB1 knockout MEFs. Markus Ehrat and Jan van Oostrum (Zeptosens—a division of Bayer (Schweiz) AG) are acknowledged for helpful input during the planning of the RPPA studies. Johann Grognum and Daniel Recheisner (Zeptosens) prepared the cell lysates for the Zeptosens Chips. Florian Freimoser and Stephan Christen (Department of Molecular Mechanisms of Disease, University of Zurich) provided valuable editorial assistance and critical input during the writing. We also thank Barbara van Loon, Nicole Grosse and Matthias Bosshard (Department of Molecular Mechanisms of Disease, University of Zurich) for help with the comet assay. The Center for Microscopy and Image Analysis at the University of Zurich is acknowledged for expert microscopy support.

*Author contributions:* A.A., A.B. and M.O.H. planned the experiments and wrote the manuscript. A.A. and A.B. performed and evaluated the data and M.O.H. supervised the study. J.T. supervised the RPPA study. F.T. and M.A. investigated cell cycle dependent PAR formation. N.K. performed the bioinformatics analysis and M.B. supervised the study. All authors reviewed the manuscript.

## FUNDING

Swiss National Science Foundation [PP00P3\_150690/1 to M.A.]; University of Zurich Association Research Talent Development Fund; University Research Priority Program ‘Integrative Human Physiology’ at the University of Zurich, the Swiss National Science Foundation Grant [310030B.138667; 310030\_157019 to M.O.H., in part]; Onco-suisse grant [KLS 02396-02-2009]; Kanton of Zurich (to M.O.H.). Funding for open access charge: Kanton of Zurich.

*Conflict of interest statement.* J.T. was Zeptosens’ Technology Manager at Bayer Technology Services GmbH and is currently Group Head for Process Analytical Technologies at the same company. The other authors declare no competing financial interests.

## REFERENCES

- Shokolenko, I., Venediktova, N., Bochkareva, A., Wilson, G.L. and Alexeyev, M.F. (2009) Oxidative stress induces degradation of mitochondrial DNA. *Nucleic Acids Res.*, **37**, 2539–2548.
- Yoshida, H., Nishikawa, M., Kiyota, T., Toyota, H. and Takakura, Y. (2011) Increase in CpG DNA-induced inflammatory responses by DNA oxidation in macrophages and mice. *Free Radic. Biol. Med.*, **51**, 424–431.
- Zhang, Q., Itagaki, K. and Hauser, C.J. (2010) Mitochondrial DNA is released by shock and activates neutrophils via P38 map kinase. *Shock*, **34**, 55–59.
- Brinkmann, V. and Zychlinsky, A. (2012) Neutrophil extracellular traps: is immunity the second function of chromatin? *J. Cell Biol.*, **198**, 773–783.
- Collins, L.V., Hajizadeh, S., Holme, E., Jonsson, I.M. and Tarkowski, A. (2004) Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. *J. Leukoc. Biol.*, **75**, 995–1000.
- Saxena, G., Chen, J.Q. and Shalev, A. (2010) Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. *J. Biol. Chem.*, **285**, 3997–4005.
- Yoshihara, E., Chen, Z., Matsuo, Y., Masutani, H. and Yodoi, J. (2010) Thiol redox transitions by thioredoxin and thioredoxin-binding protein-2 in cell signaling. *Method Enzymol.*, **474**, 67–82.
- Lane, T., Flam, B., Lockey, R. and Kolliputi, N. (2013) TXNIP shuttling: missing link between oxidative stress and inflammasome activation. *Front Physiol.*, **4**, 50.
- Kazak, L., Reyes, A. and Holt, I.J. (2012) Minimizing the damage: repair pathways keep mitochondrial DNA intact. *Nat. Rev. Mol. Cell Biol.*, **13**, 659–671.
- Alexeyev, M., Shokolenko, I., Wilson, G. and LeDoux, S. (2013) The maintenance of mitochondrial DNA integrity—critical analysis and update. *Csh Perspect. Biol.*, **5**, a012641.
- Suzuki, N., Kamataki, A., Yamaki, J. and Homma, Y. (2008) Characterization of circulating DNA in healthy human plasma. *Clin. Chim. Acta*, **387**, 55–58.
- Hassa, P.O., Haenni, S., Elser, M. and Hottiger, M.O. (2006) Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? *Microbiol. Mol. Biol. Rev.*, **70**, 789–829.
- Hottiger, M.O., Hassa, P.O., Lüscher, B., Schüller, H. and Koch-Nolte, F. (2010) Toward a unified nomenclature for mammalian ADP-ribosyltransferases. *Trends Biochem. Sci.*, **35**, 208–219.
- Luo, X. and Kraus, W.L. (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. *Genes Dev.*, **26**, 417–432.
- Altmeyer, M., Messner, S., Hassa, P.O., Fey, M. and Hottiger, M.O. (2009) Molecular mechanism of poly(ADP-ribosylation) by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. *Nucleic Acids Res.*, **37**, 3723–3738.
- Krishnakumar, R. and Kraus, W. (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. *Mol. Cell*, **39**, 8–24.
- Schiewer, M.J., Goodwin, J.F., Han, S., Brenner, J.C., Augello, M.A., Dean, J.L., Liu, F., Planck, J.L., Ravindranathan, P., Chinnaiyan, A.M. et al. (2012) Dual roles of PARP-1 promote cancer growth and progression. *Cancer Discov.*, **2**, 1134–1149.
- Kraus, W.L. and Hottiger, M.O. (2013) PARP-1 and gene regulation: progress and puzzles. *Mol. Aspects Med.*, **34**, 1109–1123.
- David, K.K., Andrabi, S.A., Dawson, T.M. and Dawson, V.L. (2009) Parthanatos, a messenger of death. *Front. Biosci.*, **14**, 1116–1128.
- Lonskaya, I., Potaman, V.N., Shlyakhtenko, L.S., Oussatcheva, E.A., Lyubchenko, Y.L. and Soldatenkov, V.A. (2005) Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding. *J. Biol. Chem.*, **280**, 17076–17083.
- Kun, E., Kirsten, E., Mendeleyev, J. and Ordahl, C. (2004) Regulation of the enzymatic catalysis of poly(ADP-ribose) polymerase by dsDNA, polyamines, Mg<sup>2+</sup>, Ca<sup>2+</sup>, histones H1 and H3, and ATP. *Biochemistry*, **43**, 210–216.
- Thomas, C.J., Kotova, E., Andrade, M., Adolf-Bryfogle, J., Glaser, R., Regnard, C. and Tulin, A.V. (2014) Kinase-mediated changes in nucleosome conformation trigger chromatin decondensation via poly(ADP-Ribosylation). *Mol. Cell*, **53**, 831–842.
- Osmanov, T., Ugrinova, I. and Pasheva, E. (2013) The chaperone like function of the nonhistone protein HMGB1. *Biochem. Bioph. Res. Co.*, **432**, 231–235.
- Joshi, S.R., Sarpong, Y.C., Peterson, R.C. and Scovell, W.M. (2012) Nucleosome dynamics: HMGB1 relaxes canonical nucleosome structure to facilitate estrogen receptor binding. *Nucleic Acids Res.*, **40**, 10161–10171.
- Bonaldi, T., Langst, G., Strohner, R., Becker, P.B. and Bianchi, M.E. (2002) The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. *EMBO J.*, **21**, 6865–6873.
- Watson, M., Stott, K., Fischl, H., Cato, L. and Thomas, J.O. (2014) Characterization of the interaction between HMGB1 and H3—a possible means of positioning HMGB1 in chromatin. *Nucleic Acids Res.*, **42**, 848–859.
- Celona, B., Weiner, A., Di Felice, F., Mancuso, F.M., Cesarini, E., Rossi, R.L., Gregory, L., Baban, D., Rossetti, G., Grianti, P. et al. (2011) Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. *PLoS Biol.*, **9**, e1001086.

28. Ugrinova, I., Pasheva, E.A., Armengaud, J. and Pashev, I.G. (2001) In vivo acetylation of HMGB1 protein enhances its binding affinity to distorted DNA structures. *Biochemistry*, **40**, 14655–14660.
29. Youn, J.H. and Shin, J.S. (2006) Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. *J. Immunol.*, **177**, 7889–7897.
30. Zhang, Q. and Wang, Y. (2008) High mobility group proteins and their post-translational modifications. *Biochim. Biophys. Acta*, **1784**, 1159–1166.
31. Paull, T.T., Haykinson, M.J. and Johnson, R.C. (1993) The nonspecific DNA-binding and -bending proteins HMGB1 and HMGB2 promote the assembly of complex nucleoprotein structures. *Genes Dev.*, **7**, 1521–1534.
32. Cohen-Armon, M. (2007) PARP-1 activation in the ERK signaling pathway. *Trends Pharmacol. Sci.*, **28**, 556–560.
33. Cohen-Armon, M., Visochek, L., Rozensal, D., Kalal, A., Geistrikh, I., Klein, R., Bendetz-Nezer, S., Yao, Z. and Seger, R. (2007) DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. *Mol. Cell*, **25**, 297–308.
34. Kauppinen, T., Chan, W., Suh, S., Wiggins, A., Huang, E. and Swanson, R. (2006) Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. *Proc. Natl. Acad. Sci. U.S.A.*, **103**, 7136–7141.
35. Zhang, S., Lin, Y., Kim, Y.S., Hande, M.P., Liu, Z.G. and Shen, H.M. (2007) c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation. *Cell Death Differ.*, **14**, 1001–1010.
36. Bauer, P.I., Farkas, G., Buday, L., Mikala, G., Meszaros, G., Kun, E. and Farago, A. (1992) Inhibition of DNA binding by the phosphorylation of poly ADP-ribose polymerase protein catalysed by protein kinase C. *Biochem. Biophys. Res. Commun.*, **187**, 730–736.
37. Hegedus, C., Lakatos, P., Olah, G., Toth, B.I., Gergely, S., Szabo, E., Biro, T., Szabo, C. and Virag, L. (2008) Protein kinase C protects from DNA damage-induced necrotic cell death by inhibiting poly(ADP-ribose) polymerase-1. *FEBS Lett.*, **582**, 1672–1678.
38. Tanaka, Y., Koide, S.S., Yoshihara, K. and Kamiya, T. (1987) Poly(ADP-ribose) synthetase is phosphorylated by protein kinase C in vitro. *Biochem. Biophys. Res. Commun.*, **148**, 709–717.
39. Mizuguchi, H., Terao, T., Kitai, M., Ikeda, M., Yoshimura, Y., Das, A.K., Kitamura, Y., Takeda, N. and Fukui, H. (2011) Involvement of protein kinase Cdelta/extracellular signal-regulated kinase/poly(ADP-ribose) polymerase-1 (PARP-1) signaling pathway in histamine-induced up-regulation of histamine H1 receptor gene expression in HeLa cells. *J. Biol. Chem.*, **286**, 30542–30551.
40. Jacobs, J.P., Jones, C.M. and Baille, J.P. (1970) Characteristics of a human diploid cell designated MRC-5. *Nature*, **227**, 168–170.
41. Nichols, W.W., Murphy, D.G., Cristofalo, V.J., Toji, L.H., Greene, A.E. and Dwight, S.A. (1977) Characterization of a new human diploid cell strain, IMR-90. *Science*, **196**, 60–63.
42. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with the Folin phenol reagent. *J. Biol. Chem.*, **193**, 265–275.
43. Dignam, J.D., Lebovitz, R.M. and Roeder, R.G. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.*, **11**, 1475–1489.
44. Pawlak, M., Schick, E., Bopp, M.A., Schneider, M.J., Oroszlan, P. and Ehrat, M. (2002) Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. *Proteomics*, **2**, 383–393.
45. Bluwstein, A., Kumar, N., Leger, K., Traenkle, J., Oostrum, J., Rehrauer, H., Baudis, M. and Hottiger, M.O. (2013) PKC signaling prevents irradiation-induced apoptosis of primary human fibroblasts. *Cell Death Dis.*, **4**, e498.
46. Voshol, H., Ehrat, M., Traenkle, J., Bertrand, E. and van Oostrum, J. (2009) Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. *FEBS J.*, **276**, 6871–6879.
47. Lloyd, S.P. (1982) Least squares quantization in PCM. *IEEE Trans. Inf. Theory*, **28**, 128–137.
48. Bevington, P.R. (2002) *Data Reduction and Error Analysis for the Physical Sciences*. 3rd edn, McGraw-Hill, NY.
49. Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M. et al. (2003) TM4: a free, open-source system for microarray data management and analysis. *Biotechniques*, **34**, 374–378.
50. Zar, J.H. (2009) *Biostatistical Analysis*. 5th edn, Prentice Hall, Upper Saddle River, NJ.
51. Schaefer, C.F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T. and Buetow, K.H. (2009) PID: the pathway interaction database. *Nucleic Acids Res.*, **37**, D674–D679.
52. Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. and Hirakawa, M. (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. *Nucleic Acids Res.*, **38**, D355–D360.
53. Ihaka, R. and Gentleman, R. (1996) R: A language for data analysis and graphics. *J. Comput. Graph. Stat.*, **5**, 299–314.
54. Reiner, A., Yekutieli, D. and Benjamini, Y. (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. *Bioinformatics*, **19**, 368–375.
55. Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A., Minguez, P., Doerks, T., Stark, M., Muller, J., Bork, P. et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res.*, **39**, D561–D568.
56. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B. and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.*, **13**, 2498–2504.
57. Altmeier, M., Toledo, L., Gudjonsson, T., Grofte, M., Rask, M.B., Lukas, C., Akimov, V., Blagoev, B., Bartek, J. and Lukas, J. (2013) The chromatin scaffold protein SAFB1 renders chromatin permissive for DNA damage signaling. *Mol. Cell*, **52**, 206–220.
58. Toledo, L.I., Altmeier, M., Rask, M.B., Lukas, C., Larsen, D.H., Povlsen, L.K., Bekker-Jensen, S., Mailand, N., Bartek, J. and Lukas, J. (2013) ATR prohibits replication catastrophe by preventing global exhaustion of RPA. *Cell*, **155**, 1088–1103.
59. Newton, A.C. (2010) Protein kinase C: poised to signal. *Am. J. Physiol. Endocrinol. Metab.*, **298**, E395–E402.
60. Ali, A.A., Timinszky, G., Arribas-Bosacoma, R., Kozlowski, M., Hassa, P.O., Hassler, M., Ladurner, A.G., Pearl, L.H. and Oliver, A.W. (2012) The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. *Nat. Struct. Mol. Biol.*, **19**, 685–692.
61. Tokui, T., Inagaki, M., Nishizawa, K., Yatani, R., Kusagawa, M., Ajiro, K., Nishimoto, Y., Date, T. and Matsukage, A. (1991) Inactivation of DNA-Polymerase Beta by In vitro Phosphorylation with Protein-Kinase-C. *J. Biol. Chem.*, **266**, 10820–10824.
62. Ugrinova, I., Zlateva, S. and Pasheva, E. (2012) The effect of PKC phosphorylation on the "architectural" properties of HMGB1 protein. *Mol. Biol. Rep.*, **39**, 9947–9953.
63. Oh, Y.J., Youn, J.H., Ji, Y., Lee, S.E., Lim, K.J., Choi, J.E. and Shin, J.S. (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. *J. Immunol.*, **182**, 5800–5809.
64. Ditsworth, D., Zong, W.X. and Thompson, C.B. (2007) Activation of poly(ADP-ribose) polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. *J. Biol. Chem.*, **282**, 17845–17854.
65. Yang, M., Liu, L., Xie, M., Sun, X., Yu, Y., Kang, R., Yang, L., Zhu, S., Cao, L. and Tang, D. (2015) Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. *Autophagy*, **11**, 214–224.
66. Vogel, C., Silva, G.M. and Marcotte, E.M. (2011) Protein expression regulation under oxidative stress. *Mol. Cell Proteomics*, **10**, M111009217.
67. Ju, B.-G., Solum, D., Song, E., Lee, K.-J., Rose, D., Glass, C. and Rosenfeld, M. (2004) Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMKinase I/delta-dependent neurogenic gene activation pathway. *Cell*, **119**, 815–829.
68. Midorikawa, R., Takei, Y. and Hirokawa, N. (2006) KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity. *Cell*, **125**, 371–383.
69. Bentle, M., Reinicke, K., Bey, E., Spitz, D. and Boothman, D. (2006) Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. *J. Biol. Chem.*, **281**, 33684–33696.
70. Sato, H., Takeo, T., Liu, Q., Nakano, K., Osanai, T., Suga, S., Wakui, M. and Wu, J. (2009) Hydrogen peroxide mobilizes Ca<sup>2+</sup> through two

- distinct mechanisms in rat hepatocytes. *Acta Pharmacol. Sinica*, **30**, 78–89.
71. Hong, J.H., Moon, S.J., Byun, H.M., Kim, M.S., Jo, H., Bae, Y.S., Lee, S.I., Bootman, M.D., Roderick, H.L., Shin, D.M. *et al.* (2006) Critical role of phospholipase C $\gamma$ 1 in the generation of H<sub>2</sub>O<sub>2</sub>-evoked [Ca<sup>2+</sup>]<sub>i</sub> oscillations in cultured rat cortical astrocytes. *J. Biol. Chem.*, **281**, 13057–13067.
72. Lee, S.R., Yang, K.S., Kwon, J., Lee, C., Jeong, W. and Rhee, S.G. (2002) Reversible inactivation of the tumor suppressor PTEN by H<sub>2</sub>O<sub>2</sub>. *J. Biol. Chem.*, **277**, 20336–20342.
73. Bartha, E., Solti, I., Kereskai, L., Lantos, J., Plozer, E., Magyar, K., Szabados, E., Kalai, T., Hideg, K., Halmosi, R. *et al.* (2009) PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. *Cardiovasc. Res.*, **83**, 501–510.
74. Gagne, J.P., Moreel, X., Gagne, P., Labelle, Y., Droit, A., Chevalier-Pare, M., Bourassa, S., McDonald, D., Hendzel, M.J., Prigent, C. *et al.* (2009) Proteomic investigation of phosphorylation sites in poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase. *J. Proteome Res.*, **8**, 1014–1029.
75. Mizuguchi, H., Miyagi, K., Terao, T., Sakamoto, N., Yamawaki, Y., Adachi, T., Ono, S., Sasaki, Y., Yoshimura, Y., Kitamura, Y. *et al.* (2012) PMA-induced dissociation of Ku86 from the promoter causes transcriptional up-regulation of histamine H(1) receptor. *Sci. Rep.*, **2**, 916.
76. Konat, G.W. (2003) H<sub>2</sub>O<sub>2</sub>-induced higher order chromatin degradation: a novel mechanism of oxidative genotoxicity. *J. Biosci.*, **28**, 57–60.
77. Shin, J.H., Lee, H.K., Lee, H.B., Jin, Y. and Lee, J.K. (2014) Ethyl pyruvate inhibits HMGB1 phosphorylation and secretion in activated microglia and in the postischemic brain. *Neurosci. Lett.*, **558**, 159–163.
78. Burkle, A. and Virag, L. (2013) Poly(ADP-ribose): PARadigms and PARadoxes. *Mol. Aspects Med.*, **34**, 1046–1065.
79. Scaffidi, P., Misteli, T. and Bianchi, M.E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*, **418**, 191–195.
80. Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R. and Tsung, A. (2008) HMGB1: endogenous danger signaling. *Mol. Med.*, **14**, 476–484.
81. Davis, K., Banerjee, S., Friggeri, A., Bell, C., Abraham, E. and Zerfaoui, M. (2012) Poly(ADP-ribosylation) of high mobility group box 1 (HMGB1) protein enhances inhibition of efferocytosis. *Mol. Med.*, **18**, 359–369.